How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about selpercatinib

Marketing authorisation indication

2.1 Selpercatinib (Retsevmo, Elli Lily) is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for 60 capsules of selpercatinib (80 mg) is £4,680 (excluding VAT; BNF online, accessed July 2021). The company's estimated cost for a 28‑day cycle of selpercatinib is £8,736.00.

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.